The antidiabetic potential was explored using a panel of in vitro targets underlying metabolic changes in diabetes, namely the capacity to inhibit the activity of enzymes involved in the metabolism of glucose (aldose reductase) and carbohydrates (α-glucosidase and α-amylase) and to manage oxidative stress through a nitric oxide and superoxide anion radical scavenging ability and lipid peroxidation protection. This evidence concerns the gene AKR1B1 and diabetes mellitus.